Total Payments
$11,747
2024 Payments
$261.00
Companies
20
Transactions
49
Medicare Patients
9,267
Medicare Billing
$3.2M
Payment Breakdown by Category
Research$11,100 (94.5%)
Food & Beverage$567.11 (4.8%)
Education$80.01 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11,100 | 15 | 94.5% |
| Food and Beverage | $567.11 | 30 | 4.8% |
| Education | $80.01 | 4 | 0.7% |
Payments by Type
Research
$11,100
15 transactions
General
$647.12
34 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $11,100 | 15 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $90.88 | 5 | $0 (2024) |
| Gilead Sciences, Inc. | $81.30 | 4 | $0 (2024) |
| Janssen Biotech, Inc. | $50.41 | 3 | $0 (2023) |
| Eisai Inc. | $45.82 | 2 | $0 (2024) |
| Exelixis Inc. | $44.15 | 1 | $0 (2017) |
| Bayer Healthcare Pharmaceuticals Inc. | $42.22 | 2 | $0 (2024) |
| Celgene Corporation | $39.76 | 2 | $0 (2024) |
| PFIZER INC. | $33.63 | 2 | $0 (2024) |
| GENZYME CORPORATION | $31.72 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $261.00 | 12 | Gilead Sciences, Inc. ($49.47) |
| 2023 | $179.46 | 9 | Novartis Pharmaceuticals Corporation ($29.34) |
| 2022 | $11,173 | 20 | Janssen Scientific Affairs, LLC ($11,100) |
| 2021 | $35.86 | 3 | Acrotech Biopharma LLC ($23.94) |
| 2019 | $12.50 | 1 | Novartis Pharmaceuticals Corporation ($12.50) |
| 2018 | $14.45 | 1 | Janssen Biotech, Inc. ($14.45) |
| 2017 | $71.24 | 3 | Exelixis Inc. ($44.15) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/29/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $30.74 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.97 | General |
| Category: Hematology | ||||||
| 06/27/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.13 | General |
| 06/05/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $23.81 | General |
| 05/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.04 | General |
| Category: Oncology | ||||||
| 04/30/2024 | Medtronic, Inc. | OSTEOCOOL RF ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 04/04/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Oncology | ||||||
| 03/21/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: ONCOLOGY | ||||||
| 03/06/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $22.18 | General |
| Category: Oncology | ||||||
| 02/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.34 | General |
| 01/10/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $19.22 | General |
| 12/29/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.91 | General |
| 11/02/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $24.79 | General |
| Category: Hematology | ||||||
| 10/05/2023 | Amgen Inc. | Nplate (Biological), Vectibix | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: Hematology | ||||||
| 09/21/2023 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $17.51 | General |
| 09/08/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: Oncology | ||||||
| 08/10/2023 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: Oncology | ||||||
| 07/27/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Oncology | ||||||
| 03/14/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $15.08 | General |
| Category: Oncology | ||||||
| 11/15/2022 | Janssen Scientific Affairs, LLC | — | — | Cash or cash equivalent | $100.00 | Research |
| Study: MYLUNG | ||||||
| 11/15/2022 | Janssen Scientific Affairs, LLC | — | — | Cash or cash equivalent | $100.00 | Research |
| Study: MYLUNG | ||||||
| 11/15/2022 | Janssen Scientific Affairs, LLC | — | — | Cash or cash equivalent | $100.00 | Research |
| Study: MYLUNG | ||||||
| 10/06/2022 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MYLUNG | Janssen Scientific Affairs, LLC | $11,100 | 15 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 1,868 | 35,475 | $3.0M | $654,211 |
| 2022 | 39 | 2,115 | 40,336 | $3.1M | $695,172 |
| 2021 | 40 | 2,353 | 41,314 | $3.2M | $778,458 |
| 2020 | 46 | 2,931 | 62,263 | $4.5M | $1.1M |
Total Patients
9,267
Total Services
179,388
Medicare Billing
$3.2M
Procedure Codes
161
All Medicare Procedures & Services
161 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 11,200 | $1.5M | $481,017 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 122 | 269 | $98,992 | $23,557 | 23.8% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 17 | 9,415 | $188,300 | $22,395 | 11.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 61 | 218 | $154,126 | $20,760 | 13.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 14 | 18 | $86,436 | $19,800 | 22.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 220 | 330 | $82,500 | $18,704 | 22.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 14 | 86 | $316,050 | $10,262 | 3.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 266 | 793 | $15,860 | $6,661 | 42.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 218 | 624 | $39,936 | $6,458 | 16.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 259 | 785 | $28,260 | $5,974 | 21.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 55 | 276 | $43,332 | $5,892 | 13.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 53 | 53 | $29,945 | $5,593 | 18.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 29 | 89 | $30,616 | $4,214 | 13.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 38 | 92 | $28,796 | $4,204 | 14.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 76 | $16,036 | $4,169 | 26.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 23 | 89 | $14,329 | $1,900 | 13.3% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 15 | 19 | $12,483 | $1,543 | 12.4% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 37 | 89 | $5,340 | $1,189 | 22.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 14 | $4,998 | $1,093 | 21.9% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 16 | 47 | $6,815 | $1,052 | 15.4% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 17 | 156 | $67,236 | $990.90 | 1.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 29 | 89 | $8,544 | $915.45 | 10.7% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 23 | 7,350 | $36,750 | $839.80 | 2.3% |
| 83550 | Iron binding capacity | Office | 2023 | 37 | 89 | $3,115 | $762.73 | 24.5% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 11 | 36 | $3,384 | $648.72 | 19.2% |
About Dr. Habib Ghaddar, M.D
Dr. Habib Ghaddar, M.D is a Medical Oncology healthcare provider based in Weslaco, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043259476.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Habib Ghaddar, M.D has received a total of $11,747 in payments from pharmaceutical and medical device companies, with $261.00 received in 2024. These payments were reported across 49 transactions from 20 companies. The most common payment nature is "" ($11,100).
As a Medicare-enrolled provider, Ghaddar has provided services to 9,267 Medicare beneficiaries, totaling 179,388 services with total Medicare billing of $3.2M. Data is available for 4 years (2020–2023), covering 161 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Weslaco, TX
- Active Since 06/04/2006
- Last Updated 01/31/2018
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1043259476
Products in Payments
- Lenvima (Drug) $45.82
- Cabometyx (Drug) $44.15
- REBLOZYL (Biological) $39.76
- IBRANCE (Drug) $33.63
- TASIGNA (Drug) $29.34
- PROMACTA (Drug) $26.80
- DARZALEX (Biological) $24.19
- BELEODAQ (Drug) $23.94
- OSTEOCOOL RF ABLATION SYSTEM (Device) $23.46
- Stivarga (Drug) $22.18
- SCEMBLIX (Drug) $21.14
- Nubeqa (Drug) $20.04
- ZEPZELCA (Drug) $19.31
- OJJAARA (Drug) $17.60
- Nplate (Biological) $16.98
- SARCLISA (Biological) $16.40
- THYROGEN (Drug) $15.32
- Erleada (Drug) $14.45
- KISQALI (Drug) $13.60
- TIVDAK (Biological) $13.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.